Simulations Plus (SLP) Q3 2026 Earnings Beat Estimates

Simulations Plus (NASDAQ:SLP) Exceeds Estimates in Q3 2026 Earnings Report

• Simulations Plus (NASDAQ:SLP) reported earnings per share (EPS) of $0.30, significantly surpassing the analyst estimate of $0.23.
• The company achieved revenue of $21.89 million, exceeding the $20.90 million estimate for the quarter.
• Simulations Plus demonstrated a substantial improvement in profitability, posting a net income of $3.60 million, a significant turnaround from a net loss of $67.30 million in the prior year.

Simulations Plus (NASDAQ:SLP) is a company that provides modeling and simulation software for drug discovery and development. This biotech software helps pharmaceutical companies predict how a drug might behave in the human body. Simulations Plus recently reported its financial results for the third quarter of fiscal year 2026, showing strong financial performance.

Simulations Plus reports an earnings per share (EPS) of $0.30, surpassing the consensus analyst estimate of $0.23. EPS is a company's profit divided by its number of common shares, indicating profitability. The company also announces revenue of $21.89 million, which exceeds the estimated $20.90 million for the quarter.

This revenue performance represents a 7% increase compared to the same period last year. The growth is mainly driven by a 20% rise in services revenue, which reaches $9.30 million. In contrast, the company’s software revenue remains flat at $12.60 million, indicating uneven growth across its business segments.

Simulations Plus demonstrates a significant improvement in profitability, posting a net income of $3.60 million. This marks a substantial turnaround from the third quarter of fiscal 2025, which saw a net loss of $67.30 million. That loss was mainly due to a large $77.20 million non-cash impairment charge.

These positive results come after a challenging period for Simulations Plus. As highlighted by GlobeNewswire, the law firm Johnson Fistel is investigating the company. The investigation follows a significant revenue guidance cut and the dismissal of its auditor in 2025, which caused its stock price to decline.